Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Drug Shortage Advice: Talk To Us Early; We’ll Be Discreet

This article was originally published in The Pink Sheet Daily

Executive Summary

Manufacturers shouldn’t be afraid to work with FDA on preventing drug shortages for fear of public shaming, agency says.

You may also be interested in...

FDA’s Priority Reviews May Have Helped Reduce New Drug Shortages

But agency's policy changes have failed to ameliorate ongoing shortages, GAO finds.

Drug Shortage Analysis Puts FDA At Loggerheads With GAO

GAO says ongoing drug shortages are increasing, but FDA says they are flattening; contrasting definitions of “shortage” produce the disparate results.

Early Notification Helping to Resolve Drug Shortages

Despite a growing number of shortages, FDA has helped to prevent many more through its early notification program. An agency official predicted that shortages will be fewer this year thanks to combined FDA and industry efforts and intervention strategies.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts